Stocktoria

4D Molecular Therapeutics, Inc. FDMT

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-12-11

4D Molecular Therapeutics, Inc. statistics & valuation

Market cap$606.4M
P / S7.1×
P / B1.2×
Net margin-164.4%
Return on equity-27.7%
FCF margin-128.6%
Return on capital-30.5%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-705.80% -416.50% -395.40% -3435.40% -486.60% -434778.40% -164.40% 2019202020212022202320242025
Gross margin (%)
2019202020212022202320242025
Operating margin (%)
-726.70% -416.30% -395.50% -3516.50% -544.60% -507678.40% -187.20% 2019202020212022202320242025
Return on equity (%)
-22.10% -22.30% -46.50% -32.80% -31.50% -27.70% 2019202020212022202320242025
Shares outstanding
5.2M 26.7M 32.2M 32.6M 43.1M 53.9M 57.9M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-84.70% -19.70% -20.20% -41.10% -29.70% -28.70% -24.70% 2019202020212022202320242025
Free cash flow margin (%)
-571.30% -381.30% -433.80% -3139.10% -379.10% -373975.70% -128.60% 2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$2.57 -$3.32 -$2.58 -$2.98 -$2.42 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin-187.2%-507678.4%-544.6%-3516.5%-395.5%-416.3%-726.7%
Net margin-164.4%-434778.4%-486.6%-3435.4%-395.4%-416.5%-705.8%
FCF margin-128.6%-373975.7%-379.1%-3139.1%-433.8%-381.3%-571.3%
Return on assets-24.7%-28.7%-29.7%-41.1%-20.2%-19.7%-84.7%
Return on equity-27.7%-31.5%-32.8%-46.5%-22.3%-22.1%67.6%
Current ratio9.3914.9215.6514.0215.6916.884.05

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.